OCTIMET Oncology NV, a clinical-stage Belgian biotech company, is pleased to announce that both proof-of mechanism was shown and a recommended phase II dose (RP2D) has been determined in the ongoing phase I/II clinical study of the company’s lead asset OMO-1.

Beerse (Belgium), 11th February 2019 – OCTIMET Oncology NV, a translational accelerator with a focus on the development of highly specific oral MET kinase inhibitors having additional differentiating properties (licensed from Janssen Pharmaceutical companies of Johnson and Johnson in January 2017), announces the successful determination of both proof-of-mechanism by complete inhibition of the target post dosing and a RP2D for OMO-1 from the monotherapy module of its multi-arm, multi-centre, Phase I/II clinical trial (NCT03138083). This solid tumour patient trial is primarily evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of the MET kinase inhibitor OMO-1 alone and in combination with anti-cancer treatments.

Glen Clack, CMO of OCTIMET Oncology NV: “Proof of target engagement is a key element for evaluating potential investment in drug development. A large number of drug candidates have failed in clinical trials, not only due to lack of efficacy but also non-verification of the predicted pharmacological mechanism of action. Target engagement is therefore one of the key elements to reduce the high failure rates in clinical trials. OCTIMET has clearly shown inhibition of the target in tissue biopsies post OMO-1 dosing, and importantly this has been done at doses below the recommended phase 2 dose (RP2D); this dose has now been taken into a formal assessment of clinical proof of concept in the monotherapy setting”.

Timothy Perera, CEO of OCTIMET Oncology NV: “These observations represent strong confirmation that OMO-1 is able to fully inhibit the intended target and show signs of real clinical benefit in these late stage biomarker selected cancer patients. It is very encouraging that OMO-1 seems to do this without many of the ‘class events’ seen with other MET inhibitors. The emerging data supports existing preclinical and healthy volunteer study data that has previously been generated with this agent confirming OMO-1 to be a differentiated highly selective MET kinase inhibitor that could help meet an unmet clinical need.”

About OCTIMET OCTIMET Oncology NV acts as a translational accelerator, focusing on creating value for patients and investors by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centred biomarker approaches. OCTIMET was set-up in 2016 and is backed by leading national and international life sciences investors since January 2017. OCTIMET is resident company of Johnson & Johnson Innovation - JLABS @ BE in Beerse (Belgium), a premier life science incubator program. The current focus is on its clinical stage lead asset OMO-1, a highly selective small molecule MET kinase inhibitor that is developed using specific patient selection biomarkers.

Media Contacts:

Dr Timothy Perera, CEO, OCTIMET Oncology NV
Telephone: +32 (0)473 558 353 -  E-Mail:  - www.octimet.com